Bayer's September Court Date Looms as Crop Science Strength Masks a Thinner Per-Share Bottom Line

Bayer's Q2 revenue rose 2.2%, but core EPS fell 16.7%. A September court hearing on the Roundup settlement and November Q3 results are pivotal.

The calendar at Bayer is tightening around two very different milestones. One is a courtroom in Missouri, where a rescheduled hearing on the company's glyphosate settlement could reshape its legal liabilities for years to come. The other is the November 3 release of third-quarter results, the next hard test of whether the operating engine can keep compensating for a sluggish pharma division.

Between now and then, investors are left weighing a second-quarter scorecard that showed genuine operational momentum alongside a notable deterioration in per-share earnings. Revenue climbed 2.2 percent on a currency- and portfolio-adjusted basis to EUR 10.872 billion, while adjusted EBITDA rose 1.9 percent to EUR 2.144 billion. Crop Science, the agricultural division, delivered the standout performance with a 30.2 percent jump in adjusted earnings, helped by firmer prices and lower production costs.

Yet the headline per-share metric told a less flattering story. Core earnings per share slid 16.7 percent to EUR 0.95, underscoring that top-line growth is not automatically translating into shareholder returns. Consumer Health also slipped, posting a 3.6 percent decline in adjusted earnings as marketing spending on newer products weighed on the division.

Management nonetheless reaffirmed its full-year guidance for 2026, a signal that the underlying business remains on track despite the legal overhang. The share price, at EUR 48.32, sits roughly 10 percent below its 52-week high of EUR 53.86 — a modest pullback after a 31 percent run from the start of the year, rather than a reversal of the broader trend.

The more immediate focus, however, is the September 14 hearing at the Missouri Circuit Court to approve the Roundup class settlement. That date was pushed back from an earlier slot to allow the court to process opt-out requests from plaintiffs who want to withdraw from the deal following a June ruling by the US Supreme Court. The justices held that federal requirements governing glyphosate approval take precedence over state law, a decision that undercuts thousands of lawsuits alleging missing cancer warnings and complicates the calculus for those considering whether to stay in the settlement.

The agreement itself carries a price tag of up to $7.25 billion, payable over a maximum of 21 years. Until the court grants final approval, the deal remains legally in limbo — and the delay is a reminder that the post-Supreme Court landscape is more intricate than originally anticipated. Each additional legal special charge, such as the EUR 172 million booked in the second quarter, tightens the financial room to maneuver at a time when net financial debt already stood at EUR 33.647 billion at the end of June, up 3.5 percent from the prior quarter.

Bayer has taken steps to shore up its balance sheet in the meantime. In mid-July, the company placed US-dollar bonds worth $5 billion with maturities ranging from five to thirty years, adding a liquidity cushion that could prove critical depending on how many plaintiffs ultimately walk away from the settlement. A wave of opt-outs would not only jeopardize the agreement in its current form but could also make it more expensive than originally budgeted.

The bullish case rests on the combination of a manageable opt-out rate and continued momentum in the field. Crop Science is growing at a double-digit clip, and the pharma pipeline is generating regulatory wins that could eventually translate into revenue. Britain's MHRA approved Kerendia (finerenone) in April for adults with symptomatic chronic heart failure and an ejection fraction of at least 40 percent, following a Chinese approval in May. Elsewhere, Lynkuet received UK approval for treating hot flashes linked to breast cancer therapy.

Should marketing costs for newer drugs eventually convert into higher sales, the pharma division could emerge from its soft patch. And if the court signs off on the settlement in September, Bayer would gain a measure of certainty over one of the largest overhangs of the past several years.

The bearish scenario is equally clear. A rising number of opt-outs could unravel the settlement or inflate its cost, and another postponement would signal that the legal path remains fraught. The nearly one-fifth decline in core EPS is a reminder that operational improvements at the revenue and EBITDA level do not automatically flow through to per-share results. Additional borrowing, while boosting liquidity, also weighs on future interest expenses.

For now, the stock trades roughly 88 percent above its 52-week low of EUR 25.78, a recovery that has been built on the strength of the agricultural business and steady pipeline progress. Whether that recovery holds depends on the September hearing and, beyond it, on whether Crop Science can keep carrying the load until pharma regains its footing. The November 3 results will provide the next clear read on that question.